ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
AstraZeneca's Imfinzi survival win shores up the one lung cancer advantage it has
May 29, 2018AstraZeneca’s Imfinzi already has an FDA approval in the lung cancer maintenance setting under its belt, something none of its rivals will be able to say for a while. And Friday, it hit another key benchmark to stretch out that lead. -
Cancer drug study placed on hold after patient death
March 14, 2018US regulators have placed on hold a clinical trial testing a combination of Advaxis’ axalimogene filolisbac and AstraZeneca's Imfinzi after a patient died from respiratory failure. -
Imfinzi Granted Breakthrough Therapy Designation by US FDA
August 02, 2017AstraZeneca and MedImmune announced the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Imfinzi (durvalumab) for the treatment of patients... -
Imfinzi wins breakthrough therapy designation
August 01, 2017AstraZeneca and MedImmune, have today announced that the US Food and Drug Administration has granted breakthrough therapy designation for Imfinzi for the treatment of patients with locally-advanced, unresectable non-small cell lung cancer…
Pharma Sources Insight January 2025
